SLC6A3 and Parkinson disease: Although there was no difference in socio-demographics and in Parkinson’s disease medications between patients who transitioned to PDP, their results showed lower DAT binding at baseline in the right and left ventral striatum and right putamen compared with those who never developed psychosis.